enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGN) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 1,330,981 shares, a growth of 16.2% from the March 31st total of 1,145,907 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average daily trading volume, of 199,435 shares, the short-interest ratio is currently 6.7 days.

Institutional Trading of enGene

Institutional investors and hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC boosted its position in shares of enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Cormorant Asset Management LP grew its position in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after buying an additional 1,676,405 shares during the period. Blue Owl Capital Holdings LP grew its position in shares of enGene by 2.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock worth $30,349,000 after buying an additional 82,831 shares during the period. Siren L.L.C. bought a new stake in shares of enGene in the 4th quarter valued at about $30,126,000. Finally, Braidwell LP raised its position in shares of enGene by 38.2% in the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after acquiring an additional 865,000 shares during the period. Institutional investors own 64.16% of the company’s stock.

enGene Trading Down 0.3%

Shares of ENGN traded down $0.02 during trading hours on Friday, hitting $7.25. 236,029 shares of the stock traded hands, compared to its average volume of 368,713. The business has a fifty day moving average of $7.83 and a 200-day moving average of $8.36. The firm has a market capitalization of $485.64 million, a PE ratio of -3.22 and a beta of -0.02. enGene has a 1-year low of $2.65 and a 1-year high of $12.25. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last released its earnings results on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.11. Analysts expect that enGene will post -2.06 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Raymond James Financial reissued a “strong-buy” rating and set a $27.00 price objective on shares of enGene in a report on Monday, March 9th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of enGene in a research note on Monday, March 9th. Oppenheimer lowered their price target on shares of enGene from $33.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. WBB Securities started coverage on shares of enGene in a report on Monday, April 13th. They set a “buy” rating and a $21.50 price objective for the company. Finally, Citigroup reissued a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.69.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.